title: [Coincidental squamous cell cancers of the esophagus and head and neck: risk and surveillance].
abstract: Patients suffering from head and neck cancer (HNC) have or will develop a second esophageal squamous cell cancer (ESCC) in 5 - 14 %. When a second esophageal neoplasm occurs in a HNC patient, the prognosis is generally determined by the ESCC, and unfortunately it is poor. Prospective clinical studies in Japan, Brazil, Taiwan, France and Germany have shown that screening or surveillance using Lugol chromoesophagoscopy enables early detection of second esophageal neoplasias. Such a surveillance results in a survival benefit for HNC patients. Vice versa, ESCC patients also have a risk of 9.3 - 11.4 % for a head and neck cancer. Periodic otolaryngeal examination and pharyngoscopy is recommended for curatively treated ESCC patients. Patients with a so-called field cancerisation of the airways and upper digestive tract thus require an interdisciplinary management and monitoring.
authors: Klinik für Innere Medizin, Gastroenterologie und Gastrointestinale Onkologie, Vivantes Klinikum Am Urban, Berlin.
authors: J
authors: J
authors: Steinberg
authors: C
authors: C
authors: Schwertner
authors: E M
authors: EM
authors: de Villiers
authors: P
authors: P
authors: Mir-Salim
authors: R
authors: R
authors: Kiesslich
authors: U
authors: U
authors: Stoelzel
authors: H
authors: H
authors: Scherübl
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000453:epidemiology*; D015897:Comorbidity; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology*; D005858:Germany / Q000453:epidemiology; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000453:epidemiology*; D008403:Mass Screening / Q000379:methods; D011159:Population Surveillance; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors